-
公开(公告)号：US08585640B2
公开(公告)日：2013-11-19
申请号：US12824343
申请日：2010-06-28
IPC分类号： A61M31/00
CPC分类号： A61M29/02 , A61M25/1029 , A61M2025/1075 , A61M2025/1084
摘要： The present invention provides a balloon which achieves diameters greater than 6 mm for securement to a catheter. The balloon includes an elastomeric generally hollow pressure expandable body which exhibits essentially radial symmetry and constant length when expanded under an internally applied minimum working pressure from an uninflated state.
摘要翻译： 本发明提供一种实现直径大于6mm的气囊，用于固定到导管。 气囊包括弹性体大体中空压力可膨胀体，其在内部施加的最小工作压力下从未充气状态膨胀时，其基本上呈径向对称性和恒定长度。
-
公开(公告)号：US20110159039A1
公开(公告)日：2011-06-30
申请号：US12871035
申请日：2010-08-30
CPC分类号： C07K14/005 , A61K9/167 , A61K31/7088 , A61K39/12 , A61K39/29 , A61K2039/53 , A61K2039/55511 , A61K2039/55555 , A61K2039/55566 , A61K2039/57 , C12N2770/24222 , C12N2770/24234
摘要： Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.
摘要翻译： 本文描述的是使用HCV E2或HCV E1E2多肽和/或HCV E2或E1E2多核苷酸引发抗体并中和针对丙型肝炎病毒（HCV）E1E2或E2抗原的结合抗体的方法。 可以使用抗E2抗体和抗E2 NOB抗体的引发，以提供模型系统来优化抗E2抗体应答和/或抗HCV NOB抗体对HCV的反应，并提供针对HCV的预防或治疗性治疗 感染。
-
3.发明申请Methods and reagents for treating, preventing and diagnosing bunyavirus infection 审中-公开治疗，预防和诊断布尼瓦病毒感染的方法和试剂公开(公告)号：US20110150911A1
公开(公告)日：2011-06-23
申请号：US10580050
申请日：2004-11-19
申请人： Qui-Lim Choo , Michael Houghton , Elizabeth Scott , Amy Weiner
发明人： Qui-Lim Choo , Michael Houghton , Elizabeth Scott , Amy Weiner
IPC分类号： A61K39/12 , C07K14/175 , C07K1/14 , C07K1/16 , C07K1/18 , C07H21/04 , C12Q1/70 , A61P37/04 , A61P31/14
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/55566 , C12N2760/12022 , C12N2760/12034
摘要： Immunogenic compositions for use in treating, preventing and diagnosing infection caused by the California (CAL) serotype of the genus Bunyavirus, such as La Crosse virus (LACV), are disclosed. Also described are reagents for use in diagnostic assays.
摘要翻译： 公开了用于治疗，预防和诊断由布尼亚病毒属的加利福尼亚（CAL）血清型如拉克罗斯病毒（LACV）引起的感染的免疫原性组合物。 还描述了用于诊断测定的试剂。
-
公开(公告)号：US07888004B2
公开(公告)日：2011-02-15
申请号：US12287006
申请日：2008-10-03
CPC分类号： C07K14/005 , A61K39/00 , A61K47/593 , A61K47/62 , A61K2039/53 , A61K2039/57 , C12N2770/24222
摘要： Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.
摘要翻译： 公开了包含可用于诊断和/或免疫原性组合物的突变非结构性丙型肝炎病毒的多肽，其中所述突变体是功能性破坏NS3的催化结构域的N-末端突变。 还公开了编码这些多肽的多核苷酸，用多核苷酸转化的宿主细胞和使用多肽和多核苷酸的方法。
-
公开(公告)号：US20110014219A1
公开(公告)日：2011-01-20
申请号：US12383425
申请日：2009-03-24
IPC分类号： A61K39/12 , C07H21/04 , A61K39/295 , A61P31/14 , C12N1/19 , C12N5/10 , A61K31/7088
CPC分类号： C12N9/14 , A61K39/00 , A61K39/12 , A61K2039/5258 , A61K2039/53 , A61K2039/545 , A61K2039/55544 , A61K2039/55555 , C07K14/005 , C07K2319/00 , C07K2319/40 , C12N2770/16022 , C12N2770/16034
摘要： Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus.
摘要翻译： 描述了引起针对诺如病毒和曙红病毒抗原的免疫应答的免疫原性组合物。 特别地，本发明涉及编码来自一种或多种诺如病毒和/或札幌病毒株的一种或多种衣壳蛋白或其它免疫原性病毒多肽的多核苷酸，这种免疫原性病毒多肽与佐剂的共表达，以及在包括免疫的应用中使用多核苷酸的方法 以及产生免疫原性病毒多肽和病毒样颗粒（VLP）。 还描述了用于生产包含一种或多种免疫原性多肽，多核苷酸，VLP和/或佐剂的诺如病毒或札幌病毒衍生的多表位融合抗原或多蛋白的免疫原性组合物的方法。 本发明的免疫原性组合物还可以含有除诺如病毒或札幌病毒抗原以外的抗原，包括可用于免疫引起腹泻疾病的病原体的抗原，例如来源于轮状病毒的抗原。
-
公开(公告)号：US20090130762A1
公开(公告)日：2009-05-21
申请号：US11974958
申请日：2007-10-17
申请人： Xavier Paliard , Michael Houghton , Mark Selby
发明人： Xavier Paliard , Michael Houghton , Mark Selby
CPC分类号： C07K14/005 , A61K48/00 , A61K2039/53 , C07K2319/00 , C12N2770/24222
摘要： The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
摘要翻译： 本发明提供一种激活丙型肝炎病毒（HCV）特异性T细胞，包括CD4 +和CD8 + T细胞的方法。 使用包含HCV NS3，NS4，NS5a和NS5b多肽的融合蛋白，编码这种融合蛋白的多核苷酸或含有这些融合物的各个组分的多肽或多核苷酸组合物来激活HCV特异性T细胞。 该方法可以在模型系统中用于开发HCV特异性免疫原性组合物，以及免疫哺乳动物抗HCV。
-
公开(公告)号：US20090098153A1
公开(公告)日：2009-04-16
申请号：US12231351
申请日：2008-09-02
申请人： Michael Houghton , Steve Coates , Mark Selby , Xavier Paliard
发明人： Michael Houghton , Steve Coates , Mark Selby , Xavier Paliard
IPC分类号： A61K39/00
CPC分类号： C07K14/005 , A61K48/00 , A61K2039/53 , C07K2319/00 , C12N2770/24222
摘要： The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
-
公开(公告)号：US20080318275A1
公开(公告)日：2008-12-25
申请号：US12077147
申请日：2008-03-17
申请人： Robert O. Ralston , Frank Marcus , Kent B. Thudium , Barbara A. Gervase , John A. Hall , Kim M. Berger , Qui-Lim Choo , Michael Houghton , George Kuo
发明人： Robert O. Ralston , Frank Marcus , Kent B. Thudium , Barbara A. Gervase , John A. Hall , Kim M. Berger , Qui-Lim Choo , Michael Houghton , George Kuo
IPC分类号： C12P21/04
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222 , Y10S530/82 , Y10S530/826 , Y10S977/802 , Y10S977/803 , Y10S977/804 , Y10S977/915 , Y10S977/918
摘要： Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
摘要翻译： 两种丙型肝炎病毒包膜蛋白（E1和E2）不表达唾液酸化。 这些蛋白质在低等真核生物或其末端糖基化被阻断的哺乳动物细胞中的重组表达导致与天然HCV糖蛋白更相似的重组蛋白质。 当通过GNA凝集素亲和力分离时，E1和E2蛋白聚集成病毒样颗粒。
-
公开(公告)号：US20080125710A1
公开(公告)日：2008-05-29
申请号：US11500794
申请日：2006-08-07
申请人： Alex R. Hobson , Michael Houghton , David R. King , Joseph E. Korleski , Brian C. Lentz , Kenneth Newcomb , Peter J. Roeber , John Streeter
发明人： Alex R. Hobson , Michael Houghton , David R. King , Joseph E. Korleski , Brian C. Lentz , Kenneth Newcomb , Peter J. Roeber , John Streeter
IPC分类号： A61M25/10
CPC分类号： A61M25/10 , A61F2/958 , A61F7/123 , A61F2007/126 , A61F2250/0067 , A61L29/041 , A61L29/085 , A61L29/126 , A61L29/146 , A61M25/1002 , A61M25/1006 , A61M25/1018 , A61M25/10184 , A61M25/1027 , A61M25/1029 , A61M25/104 , A61M2025/1031 , A61M2025/105 , A61M2025/1052 , A61M2025/1075 , A61M2205/0216 , B32B1/00 , B32B1/02 , B32B1/08 , B32B5/18 , C08J7/047 , C08J2327/18 , C08J2475/04 , Y10T428/1352 , Y10T428/1386
摘要： The present invention provides a stretchable material suitable for use in an inflatable medical device. The stretchable material has at least one reinforcing polymer layer with a top and bottom side forming a porous matrix which is imbibed with a sealing material to infiltrate and substantially seal spaces of the porous matrix and extend beyond the reinforcing polymer layer to form a surface coating.
摘要翻译： 本发明提供一种适用于充气医疗装置的伸缩性材料。 可拉伸材料具有至少一个增强聚合物层，其顶部和底部形成多孔基质，该多孔基体被密封材料吸收，以渗透并基本上密封多孔基质的空间，并延伸超过增强聚合物层以形成表面涂层。
-
公开(公告)号：US20080095800A1
公开(公告)日：2008-04-24
申请号：US12001920
申请日：2007-12-13
CPC分类号： C07K14/005 , A61K9/167 , A61K31/7088 , A61K39/12 , A61K39/29 , A61K2039/53 , A61K2039/55511 , A61K2039/55555 , A61K2039/55566 , A61K2039/57 , C12N2770/24222 , C12N2770/24234
摘要： Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.
-
-
-
-
-
-
-
-
-
搜索结果
123 条记录 (耗时 0.04 秒)
